NU-9 targets a shared underlying mechanism found in various neurodegenerative diseases. A new study from Northwestern ...

Experimental drug NU-9 — a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) — improves ...

Evidence suggests that in Parkinson’s disease, a breakdown in lysosomal function allows lipids to build up within cells. Variants of the GBA1 gene, the strongest genetic risk factor for sporadic PD, ...

Neurodegenerative diseases like Alzheimer’s and ALS involve different proteins, but they share a key problem: the proteins ...

After further analysis, the researchers found the drug relies on lysosomes, which are one of the cells' major recycling centers, and on an enzyme called cathepsin B. In Alzheimer's disease ...

After further analysis, the researchers found the drug relies on lysosomes, which are one of the cells' major recycling centers, and on an enzyme called cathepsin B. In Alzheimer's disease ...